Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells $15,204.75 in Stock

Becton, Dickinson and Company (NYSE:BDX) EVP Michael Feld sold 75 shares of the stock in a transaction that occurred on Monday, January 26th. The stock was sold at an average price of $202.73, for a total value of $15,204.75. Following the completion of the transaction, the executive vice president owned 16,431 shares in the company, valued at $3,331,056.63. This represents a 0.45% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Michael Feld also recently made the following trade(s):

• On Friday, December 26th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $196.08, for a total transaction of $14,509.92.
• On Monday, December 1st, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The stock was sold at an average price of $193.36, for a total transaction of $14,502.00.

Becton, Dickinson and Company Stock Up 1.2%

Becton, Dickinson and Company stock opened at $203.56 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.64 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $162.29 and a 1-year high of $251.99. The firm’s fifty day simple moving average is $198.54 and its 200-day simple moving average is $191.24. The company has a market capitalization of $58.00 billion, a P/E ratio of 34.92, a P/E/G ratio of 2.22 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 EPS for the quarter, topping the consensus estimate of $3.92 by $0.04. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. The firm had revenue of $5.89 billion for the quarter, compared to the consensus estimate of $5.91 billion. During the same period in the prior year, the business posted $3.81 earnings per share. The business’s quarterly revenue was up 8.3% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. Sell-side analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Investors of record on Tuesday, March 10th will be issued a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.1%. The ex-dividend date is Tuesday, March 10th. Becton, Dickinson and Company’s payout ratio is 72.04%.

Becton, Dickinson and Company announced that its board has authorized a stock buyback program on Tuesday, January 27th that authorizes the company to repurchase $10.00 million in shares. This repurchase authorization authorizes the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s board believes its shares are undervalued.

Hedge Funds Weigh In On Becton, Dickinson and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in BDX. Crux Wealth Advisors increased its position in shares of Becton, Dickinson and Company by 0.8% during the fourth quarter. Crux Wealth Advisors now owns 6,297 shares of the medical instruments supplier’s stock valued at $1,222,000 after purchasing an additional 49 shares during the period. Camelot Portfolios LLC boosted its stake in Becton, Dickinson and Company by 1.5% during the fourth quarter. Camelot Portfolios LLC now owns 3,545 shares of the medical instruments supplier’s stock worth $688,000 after buying an additional 54 shares in the last quarter. Bill Few Associates Inc. boosted its stake in Becton, Dickinson and Company by 0.7% during the second quarter. Bill Few Associates Inc. now owns 7,906 shares of the medical instruments supplier’s stock worth $1,362,000 after buying an additional 55 shares in the last quarter. McElhenny Sheffield Capital Management LLC increased its holdings in Becton, Dickinson and Company by 3.6% in the 4th quarter. McElhenny Sheffield Capital Management LLC now owns 1,590 shares of the medical instruments supplier’s stock valued at $309,000 after buying an additional 55 shares during the period. Finally, Gilbert & Cook Inc. raised its stake in shares of Becton, Dickinson and Company by 2.0% in the 2nd quarter. Gilbert & Cook Inc. now owns 2,844 shares of the medical instruments supplier’s stock valued at $490,000 after buying an additional 56 shares in the last quarter. 86.97% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Royal Bank Of Canada boosted their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a report on Tuesday, December 2nd. Jefferies Financial Group lifted their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, December 10th. Piper Sandler boosted their price objective on Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research report on Wednesday. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $209.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.